These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36283896)

  • 1. Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.
    Serra L; Webber C; Burman C; Bueti P; Gorruso M; Mather S
    Vaccine; 2022 Nov; 40(49):7014-7021. PubMed ID: 36283896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence.
    Findlow J; Knuf M
    Future Microbiol; 2019 May; 14():563-580. PubMed ID: 31091978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine.
    Quiambao B; Peyrani P; Li P; Cutler MW; Van Der Wielen M; Perez JL; Webber C
    Hum Vaccin Immunother; 2020 Jun; 16(6):1272-1279. PubMed ID: 32401600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
    Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
    Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
    Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.
    Knuf M; Romain O; Kindler K; Walther U; Tran PM; Pankow-Culot H; Fischbach T; Kieninger-Baum D; Bianco V; Baine Y; Miller J
    Eur J Pediatr; 2013 May; 172(5):601-12. PubMed ID: 23307281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
    Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix
    Dhillon S; Pace D
    Drugs; 2017 Nov; 77(17):1881-1896. PubMed ID: 29094312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children.
    Cutland CL; Peyrani P; Webber C; Newton R; Cutler M; Perez JL
    Vaccine; 2023 Jan; 41(5):1153-1160. PubMed ID: 36621408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.
    Baxter R; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M
    Pediatr Infect Dis J; 2015 Nov; 34(11):1236-43. PubMed ID: 26237742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.
    Marshall GS; Pelton SI; Robertson CA; Oster P
    Hum Vaccin Immunother; 2022 Nov; 18(6):2099142. PubMed ID: 35947774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
    Borja-Tabora CF; Montalban C; Memish ZA; Boutriau D; Kolhe D; Miller JM; Van der Wielen M
    BMC Infect Dis; 2015 Oct; 15():409. PubMed ID: 26437712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
    Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
    Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers.
    Bona G; Castiglia P; Zoppi G; de Martino M; Tasciotti A; D'Agostino D; Han L; Smolenov I
    Vaccine; 2016 Jun; 34(29):3363-70. PubMed ID: 27181507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningococcal Group A, C, W, and Y Tetanus Toxoid Conjugate Vaccine: A Review of Clinical Data in Adolescents.
    Serra LC; York LJ; Balmer P; Webber C
    J Adolesc Health; 2018 Sep; 63(3):269-279. PubMed ID: 30236996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
    Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
    Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).
    Østergaard L; Van der Wielen M; Bianco V; Miller JM
    Int J Infect Dis; 2013 Mar; 17(3):e173-6. PubMed ID: 23246368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
    Baccarini CI; Simon MW; Brandon D; Christensen S; Jordanov E; Dhingra MS
    Pediatr Infect Dis J; 2020 Oct; 39(10):955-960. PubMed ID: 32852352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review.
    Ghanem S; Hassan S; Saad R; Dbaibo GS
    Expert Opin Biol Ther; 2013 Aug; 13(8):1197-205. PubMed ID: 23815506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.